Catalyst Pharmaceuticals (NASDAQ:CPRX) Rating Lowered to “Hold” at Zacks Research

Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research firms have also recently issued reports on CPRX. Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $31.50 in a research note on Friday, May 8th. Finally, Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.17.

Catalyst Pharmaceuticals Trading Down 0.1%

Catalyst Pharmaceuticals stock opened at $31.21 on Monday. Catalyst Pharmaceuticals has a 12-month low of $19.05 and a 12-month high of $32.56. The stock has a market cap of $3.82 billion, a P/E ratio of 17.94, a PEG ratio of 0.91 and a beta of 0.72. The company has a 50-day moving average price of $26.42 and a 200 day moving average price of $24.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CPRX. Rothschild Investment LLC increased its stake in shares of Catalyst Pharmaceuticals by 1,085.7% during the third quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,520 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 630 shares in the last quarter. Clearstead Advisors LLC increased its stake in shares of Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 1,167 shares in the last quarter. Larson Financial Group LLC increased its stake in shares of Catalyst Pharmaceuticals by 552.7% during the fourth quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 1,564 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth about $39,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).